Engineered immune cells take on glioblastoma in first human trial

NCT ID NCT07193628

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new type of immunotherapy called CAR-T cells in 14 people with glioblastoma that has come back or not responded to treatment. The CAR-T cells are designed to target two proteins found on glioblastoma cells and are given directly into the fluid around the brain. The main goal is to see if the treatment is safe and to find the best dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EPC-003 CAR-T cells (a type of immune cell therapy)
What this could lead to: If successful, this could point toward a new treatment option for patients with recurrent glioblastoma, a brain cancer with few effective therapies.
What could go wrong: This is a very early, small phase 1 trial with only 14 participants. It primarily tests safety, not effectiveness. There is a risk of serious side effects from the CAR-T cells.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT GLIOBLASTOMA REFRACTORY GLIOBLASTOMA

Contacts and locations

Locations

the Second Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITING

Hangzhou, Zhejiang, 210000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.